PapersPMID:30532573
Quantifying the effects of spirulina supplementation on plasma lipid and glucose concentrations, body weight, and blood pressure.
- findings
- 7
- compound
- 1
- endpoints
- 7
- no difference found
- 2
- Study, every finding
- meta-analysis
- Dose studied, every finding
- 1 to 19 g/d across trials, 2 to 24 weeks
What moved
How to read these marks →“For the change of lipid profiles, as shown in Figure 2, the pooled result showed that spirulina supplements significantly lower the TC (12 treatment arms; WMD = −36.60 mg/dL; 95% CI: −51.87 to −21.33; P=0.0001; I =93%), LDL-C (11 treatment arms; WMD = −33.16 mg/dL; 95% CI: −50.52 to −15.75; P=0.0002; I =96%), TG (12 treatment arms; WMD = −39.20 mg/dL; 95% CI: −52.71 to −25.69; P=0.0001; I =73%), and vLDL-C (five treatment arms; WMD = −8.02 mg/dL; 95% CI: −8.77 to −7.26; P=0.0001; I =0%).”
- Decreases total cholesterol (TC)
moderate
- Effect
- −36.6 mean difference, 95% CI −51.87 to −21.33
- Population
- Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; 12 treatment arms contributed to this estimate
- Decreases triglycerides
moderatereplicated ×4
- Effect
- −39.2 mean difference, 95% CI −52.71 to −25.69
- Population
- Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; 12 treatment arms contributed to this estimate
- Decreases LDL cholesterol
moderate
- Effect
- −33.16 mean difference, 95% CI −50.52 to −15.75
- Population
- Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; 11 treatment arms contributed to this estimate
- Decreases diastolic blood pressure
moderatereplicated ×2
“For the change of BP, consumption with spirulina showed a significant decrease in DBP (four treatment arms; WMD = −7.17 mmHg; 95% CI: −8.57 to −5.78; P=0.0001; I =0%) but not SBP (four treatment arms; WMD = −3.49 mmHg; 95% CI: −7.19 to 0.21; P=0.06; I =50%).”
- Effect
- −7.17 mean difference, 95% CI −8.57 to −5.78
- Population
- Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; four treatment arms contributed to this estimate
- Decreases fasting blood glucose
moderate
“Finally, spirulina consumption significantly lowered FBG (eight treatment arms; WMD = −5.01 mg/dL; 95% CI: −9.78 to −0.24; P=0.04; I =77%).”
- Effect
- −5.01 mean difference, 95% CI −9.78 to −0.24
- Population
- Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; eight treatment arms contributed to this estimate
What did not
“No significant changes were found for body weight (seven treatment arms; WMD = −1.51 kg; 95% CI: −3.39 to 0.36; P=0.11; I =0%), BMI (five treatment arms; WMD = −0.44 (kg/m2); 95% CI: −1.87 to 0.99; P=0.54; I =71%), and HbA1c (three treatment arms; WMD = −0.34; 95% CI: −0.79 to 0.11; P=0.14; I =78%) following spirulina supplementation.”
- No detected effect on body mass index
moderatereplicated ×2
- Effect
- −0.44 mean difference, 95% CI −1.87 to 0.99
- Population
- Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; five treatment arms contributed to this estimate
- Effect
- −0.34 mean difference, 95% CI −0.79 to 0.11
- Population
- Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; three treatment arms contributed to this estimate
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Adults and children in 12 trials (14 arms): type 2 diabetes, HIV-infected, hypertension, ischemic heart disease, hyperlipidemic nephrotic syndrome
- Participants
- 807
- Comparator
- no treatment / placebo
- Duration
- not reported
- Endpoints measured
- 23